tradingkey.logo
tradingkey.logo
Search

PharmaCyte Biotech Inc

PMCB
Add to Watchlist
0.715USD
-0.026-3.51%
Close 07/02, 13:00ETQuotes delayed by 15 min
7.68MMarket Cap
LossP/E TTM

PharmaCyte Biotech Inc

0.715
-0.026-3.51%
View Detailed Chart
TradingKey 图表
Intraday
1m
30m
1h
D
W
M
D

Today

-3.51%

5 Days

-7.11%

1 Month

-1.43%

6 Months

-3.12%

Year to Date

-1.24%

1 Year

-35.59%

Key Figures
0.756Open
0.770High
55.65KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.52%Turnover Ratio
0.741Prev. Close
0.715Low
34.15KTurnover
0.33P/E Static
0.20P/B
0.00%Div Yield TTM
-6.58%ROA
1.51052wk High
1.20Volume Ratio
23.36MNet Profit
10.74MShares
-0.8906EPS TTM
0.50Beta
-19.01%ROE
0.63052wk Low
7.42%Amplitude
--Gross Margin
7.68MMarket Cap
0.38Reward/Risk
5.59%Risk Rate

Key Insights

PharmaCyte Biotech Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 219 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

PharmaCyte Biotech Inc's Score

Industry at a Glance

Industry Ranking
219 / 387
Overall Ranking
439 / 4565
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

PharmaCyte Biotech Inc Highlights

StrengthsRisks
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is -0.80, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.07M shares, increasing 24.50% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space

PharmaCyte Biotech Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

PharmaCyte Biotech Inc Info

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Ticker SymbolPMCB
CompanyPharmaCyte Biotech Inc
CEOSilverman (Joshua N)
Websitehttps://pharmacyte.com/

FAQs

What is the current price of PharmaCyte Biotech Inc (PMCB)?

The current price of PharmaCyte Biotech Inc (PMCB) is 0.71.

What is the symbol of PharmaCyte Biotech Inc?

The ticker symbol of PharmaCyte Biotech Inc is PMCB.

What is the 52-week high of PharmaCyte Biotech Inc?

The 52-week high of PharmaCyte Biotech Inc is 1.51.

What is the 52-week low of PharmaCyte Biotech Inc?

The 52-week low of PharmaCyte Biotech Inc is 0.63.

What is the market capitalization of PharmaCyte Biotech Inc?

The market capitalization of PharmaCyte Biotech Inc is 7.68M.

What is the Earnings Per Share (EPS TTM) of PharmaCyte Biotech Inc (PMCB)?

The Earnings Per Share (EPS TTM) of PharmaCyte Biotech Inc (PMCB) is 3.19.